

A

Docket No. J&J1886USCIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Miri Seiberg et al.

Confirmation No.: 6375

Serial No.

10/689.149

Art Unit: 1616

Filed

October 20, 2003

Examiner: Marina Lamm

For

Topical Anti-Cancer Compositions and Methods of Use Thereof

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 14, 2006
(Date of Deposit)

Andrea L. Colby, Req. No. 30,194
(Name of applicant, assignee, or Registered Representative)

/Andrea L. Colby/
(Signature)

November 14, 2006
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

× I	n accordance with §1.97(b), since this Information Disclosure Statement						
	ither within three months of the filing date of the above-identified						
_	national application (other than a continued prosecution application under §1.53(d)),						
	onths of the date of entry into the national stage of the above identified						
application as	set forth in §1.491, or before the mailing date of a first Office Action on						
the merits of th	ne above-identified application, or before the mailing date of a first Office						
Action after the	e filing of a request for continued examination under §1.114, no						
additional fee	is required.						
_							
•	n accordance with §1.97(c), this Information Disclosure Statement is						
being filed afte	er the period set forth in §1.97(b) above but before the mailing date of						
either a Final A	Action under §1.113 or a Notice of Allowance under §1.311, or an action						
that otherwise	closes prosecution and that it is accompanied by one of:						
[Statement in Accordance with §1.97(e) (attached); or						
[Please charge Deposit Account No. 10-0750/ / the fee						
	of <u>\$180.00</u> as set forth in §1.17(p).						
	n accordance with §1.97(d), this Information Disclosure Statement is						
	er the mailing date of either a Final Action under §1.113 or a Notice of						
	-						
	ler §1.311 but before the payment of the Issue Fee. Applicant(s)						
•	n(s) for consideration of this Information Disclosure Statement. Included						
	nt in Accordance with §1.97(e) as set forth below and the fee of \$180.00						
as set forth in	§1.17(p).						
\boxtimes	Copies of only foreign patent documents and non-patent literature are						
	cordance with 37 CFR 1.98 (a)(2).						
	There are no listed references which are not in the English language.						
	The relevance of those listed references which are not in the English						
language is as	follows:						

English language abstracts are pro	ovided for the foreign patent documents listed
on the form SB/08/A.	
	i i
Attached are copies of seal	rch report(s) from corresponding patent
application(s), which are listed on the atta	ached Submission Under MPEP 609 D.
Attached and the following	
Aπached are the following r	non-published pending patent applications
which may be deemed relevant, which ar	e listed on the attached Submission Under
MPEP 609 D.	-
<u>2</u> . 333 <u>5</u> .	•
	•
Please charge any deficiency or c	redit any overpayment to Deposit Account
No. 10-0750/J&J1886CIP1/ALC. This fo	rm is submitted in triplicate.
	Respectfully submitted,
	/Andrea L. Colby/
	Andrea L. Colby
	Reg. No. 30,194
	Attorney for Applicants
Johnson & Johnson	
One Johnson & Johnson Plaza	
New Brunswick, NJ 08933-7003 (732):524-2792	
DATED: November 14, 2006	•

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

to respond to a collection of information unless it displays a valid owns control fromber.					
Confirmation Number	6375				
Application Number	10/689,149				
Filing Date	10/20/2003				
First Named Inventor	Miri Seiberg				
Group Art Unit	1616				
Examiner Name	Marina Lamm				
Attorney Docket Number	J&J1886USCIP1				

U.S. PATENT DOCUMENTS						
		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
Exam Initials	Cite No. ¹		d Code ² known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		2004/0063593	A1	Wu et al.	04-01-2004	
	<u> </u>					
			ļ			
				FOREIGN PATENT DOCUMENTS		

			•		FOREIGN PATENT DOCUMENTS			
Initiala	Cite	Foreign Patent Document Office ³ Number ⁴ KindCode ⁵			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
	NO.	DE	4432947	Α	New Standard GmbH	03-21-1996	English Abst.	
		DE	19634206	Α	Reinke Ludwig Dr.	03-05-1998	English Abst.	
		DE	19818849,	Α	Med-Beauty AG	10-29-1998	English Abst.	
		EP	0 581 624	A1	Expanchimie SARL	02-02-1994	English Abst.	
		EP	0 581 624	B1	Expanchimie SARL	02-02-1994	English Claims	
		EP	0 582 239	A1	Rhone-Poulenc Rorer	02-09-1994	English Abst.	
		EP	0 582 239	B1	Rhone-Poulenc Rorer	02-09-1994	English Claims	
		EP	1 210 946	Α	Neutrogena Corp.	06-05-2002		
		JP	60061513	Α,	Sansei Seiyaku KK	04-09-1985	English Abst.	
		wo	99/00110	A1	Andre et al.	01-07-1999	English Abst.	
NI Č		wo	99/39682	A2	Fernandez-Kleinlein et al.	08-12-1999		
			OTHER	PRIOR	ART - NON PATENT LITERATURE DO	CUMENTS		

Exam Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published T² T²

Examiner	Date	
Signature	Considered	l

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.